Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.68
-$0.01-1.41%
OTC PK
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 0.93% | -4.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.06% | -11.68% | |||
| Operating Income | 8.06% | 11.68% | |||
| Income Before Tax | 5.12% | 16.05% | |||
| Income Tax Expenses | 13.79% | 3.57% | |||
| Earnings from Continuing Operations | 5.10% | 16.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.10% | 16.03% | |||
| EBIT | 8.06% | 11.68% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 19.74% | 48.62% | |||
| Normalized Basic EPS | 19.77% | 48.63% | |||
| EPS Diluted | 19.74% | 48.62% | |||
| Normalized Diluted EPS | 19.77% | 48.63% | |||
| Average Basic Shares Outstanding | 18.24% | 63.43% | |||
| Average Diluted Shares Outstanding | 18.24% | 63.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||